Global Parkinson Disease Drug Biomarkers Insight 2028 Report Highlights:
- Global Parkinson’s Disease Antibodies Market Opportunity: > USD 8 Billion
- Parkinson’s Disease Clinical Trials Insight: > 300 Drugs In Trials
- Parkinson’s Disease Biomarkers Sourced During Clinical Trials
- Parkinson’s Disease Insight By Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report Sample:
http://biomarkersinsights.com/parkinson-disease-biomarkers-and-clinical-trials-insight-2028
Parkinson disease is the second most commonly occurring neurodegenerative disorder. The hallmark features of pathology of PD include progressive loss of dopaminergic neurons in substantia niagra pars compacta, significantly reduced levels of dopamine in the striatum and the presence of cytoplasmic proteinaceous inclusions known as Lewy bodies. The disease is a result from m a complex interaction between environmental factors and genetic predisposition in individuals. The main class of anti-Parkinson drugs is levodopa/carbidopa, dopamine receptor agonists, monoamine oxidase type b (MAO-b) inhibitors, catechol-o-methyltransferase (COMT)-inhibitors, anticholinergics and other drugs.catechol-O-methyltransferase (COMT) inhibitors are a class of drugs used to treat Parkinson’s disease symptoms in conjunction with carbidopa-levodopa therapy. Currently, treatment with levodopa is considered as gold standard.
Despite the availability of large number of drugs, there is high medical need for the development of therapies which can target the root cause of disease, and hence are associated with minimal side effects. Currently, more than 500 clinical trials are ongoing in global Parkinson drug market, which suggests promising future of targeted therapies in the management of disease. The treatments that use small molecule α-synuclein aggregation therapy (ambroxol or Cu(II)ATSM) or monoclonal antibody (AFFITOPE PD01A, and PRX002) or gene therapy (PR001A/AAV-GAD) might be promising compared to other clinical trials/therapies for the treatment of Parkinson disease in future. For instance in 2021, US FDA has granted Fast Track designation to DA01 for the treatment of advanced Parkinson disease. DA01 is an investigational pluripotent stem cell-derived dopaminergic neuron therapy designed to replace the midbrian dopaminergic neurons lost in Parkinson disease using the Company’s cell+gene platform. By replacing these neurons, DA01 may rebuild the neural circuit and restore motor control, thereby potentially reversing the disease.
Apart from novel targeted therapies, research is also oriented towards the development of novel biomarkers for early diagnosis. The major companies have also adopted strategic alliances such as collaboration or partnerships to secure their position in the market. For instance in October 2021, Altoida has entered into collaboration with the Bioinformatics and Human Electrophysiology Laboratory (BiHELab), Department of Informatics at Ionian University. The collaboration will investigate Altoida’s medical device, an FDA Breakthrough Device being developed for for early diagnosis and prediction of Parkinson’s disease onset. Altoida and BiHELab will apply and Altoida’s technology to analysis of Parkinson’s disease progression and evaluate its efficacy in diagnosing Parkinson’s in the preclinical phase. These rising trends in the global market are expected to drive the growth during the forecast period.
As per our report findings, the global Parkinson drug market is expected to surpass US$ 8 Billion by 2028. The increasing geriatric population and surging cases of Parkinson’s disease (PD) are projected to drive the demand for the anti-Parkinson drugs market in the forthcoming years. Further, increasing investments by governments and companies for Parkinson’s disease drug research and development is another major trend in the global Parkinson drugs market. Greater patient compliance as a result of increased awareness about the benefits of the drugs, such as improved quality of life and reduction/prevention of disease co-morbidity, will also help spur patient adherence to prescribed treatment regimes. The increased sales of the drug will also have a positive impact on the growth of market.
Our report provides an in-depth analysis of the global Parkinson drug disease market and the current market trends and future estimations. The report also covers the Parkinson drugs available in the market and their patent, price, generic availability, dosage, and sales analysis. Further, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry. The major companies in the Parkinson drug market are GlaxoSmithKline plc, Pfizer, Merck, Novartis, Roche, UCB S.A, Teva Pharmaceuticals, AbbVie Inc., Mylan, Boehringer Ingelheim, Orion Pharma, amongst others.
Contact:
Preeti Dureja
Research Partner
Biomarkers Insights
www.biomarkersinsights.com